Hagar Sabry El-Hema

Dr. Hagar Sabry El-Hema

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in ACS Omega
Verified
Journal Article
Open access
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
SSSara. M. Soliman
Sara. M. Soliman
WEWagdy El-Dougdoug
Wagdy El-Dougdoug
MAMohamed H. M. Ahmed
Mohamed H. M. Ahmed
AAAbdelmotaal Abdelmajeid
Abdelmotaal Abdelmajeid
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
The pressing demand for novel antibiotics to counter drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), underscores the serious public health threat posed by antibiotic resistance. To address this issue, novel quinazoline-4-one derivatives were developed, synthesized, and evaluated in vitro against a range of pathogens, including fungi like Aspergillus fumigatus (RCMB 002008), Gram-negative bacteria like Escherichia coli (ATCC 25922), and Gram-positive bacteria like Staphylococcus aureus (ATCC 25923) and MRSA (USA300). Notably, the thieno-thiazolo-quinazoline compounds 4 and 5 demonstrated a strong ability to inhibit and disrupt MRSA USA300 biofilm formation across all tested concentrations. Furthermore, in an in vivo MRSA skin infection model, these compounds effectively reduced bacterial counts compared to both vehicle-treated and untreated control groups. To enhance understanding and provide deeper insights, ADMET and docking simulations were also conducted.

30 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
HSHaitham Emad Shehata
Haitham Emad Shehata
MHMohamed A. Hawata
Mohamed A. Hawata
ENEman Nossier
Eman Nossier
Ahmed Fikry El-sayedAhmed Fikry El-sayed
Ahmed Fikry El-sayed
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
Background: Derivatives of Pyrido[2,3-d]pyrimidine-6-carboxylate are promising multi-target scaffolds. This study focused on synthesizing 16 amino-functionalized derivatives and evaluating their dual anticancer and antibacterial activities, supported by mechanistic and computational analyses. Objectives: Design and synthesize derivatives, evaluate cytotoxicity against HeLa, HepG-2, and MCF-7 (selectivity against WI-38), investigate EGFRWT and EGFRT790M inhibition, assess cell cycle, apoptosis, and migration effects, antibacterial efficacy against E. coli and P. aeruginosa, and perform in silico ADMET, docking, molecular dynamics, DFT, and antiviral predictions. Methods: Synthesized 16 derivatives; tested for cytotoxicity, EGFR inhibition, cell cycle, apoptosis, migration; assessed antibacterial activity; performed ADMET profiling, molecular docking, molecular dynamics, and DFT calculations. Results: Derivatives 1, 2, and 7 showed highest cytotoxicity (IC50 = 3.98–17.52 μM; WI-38 IC50 = 64.07–81.65 μM). Compound 1 potently inhibited EGFRWT (IC50 = 0.093 μM) and EGFRT790M (IC50 = 0.174 μM), induced G0/G1 arrest (74.86%) and apoptosis (26.37%), and reduced MCF-7 migration (69.63%). Moderate antibacterial activity observed (MIC = 50 μg/mL). ADMET indicated favorable pharmacokinetics, low CYP inhibition, negative mutagenicity, and oral toxicity class III. Molecular dynamics confirmed stable binding (EGFRWT RMSD 3 Å; EGFRT790M 3.5–4.6 Å) with persistent hydrogen bonds. In silico antiviral evaluation suggested strong binding to HCV NS5A (–9.36 kcal/mol), SARS-CoV-2 Mpro (–9.82 kcal/mol), and E.coli DNA gyrase (–10.25 kcal/mol). Conclusions: Compound 1 exhibits dual anticancer and antibacterial activity, supported by mechanistic and computational analyses, highlighting pyrido[2,3-d]pyrimidines as promising multi-target therapeutic scaffolds.

31 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSara M. Soliman
Sara M. Soliman
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
ENEman Nossier
Eman Nossier
MHModather F. Hussein
Modather F. Hussein
ASAmr Sabry
Amr Sabry
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
Quinazolinone derivatives have been broadly studied as anti-cancer drug candidates due to their potential to inhibit key signaling pathways involved in tumor progression. In the current study, new 2-[(4-substituted-5-methylfuran-3-yl)thio]-3-phenylquinazolin-4(3H)-one derivatives (2–10) were designed and assessed for anti-cancer activity. Cytotoxicity of the compounds was tested against normal WI-38 cells and cancer cell lines HepG-2 (liver), MCF-7 (breast), and HCT-116 (colorectal). In addition, their inhibitory effects on EGFR and VEGFR-2, key targets for tumor growth and angiogenesis, were assessed. Compounds 6b and 10 showed significant cytotoxic activity, with 6b (IC₅₀ = 0.19 ± 0.03 μM) being the most effective EGFR inhibitor, over 10 (IC₅₀ = 0.51 ± 0.04 μM) and as potent as erlotinib (IC₅₀ = 0.23 ± 0.02 μM). Flow cytometry revealed that 6b induced apoptosis in 35.29% of MCF-7 cells and G₂/M phase cell cycle arrest, much better than that of untreated cells (6.81%). In silico ADMET prediction and molecular docking confirmed high EGFR binding affinity and favorable pharmacokinetic properties. Overall, compound 6b showed promising anti-cancer activity via EGFR inhibition, apoptosis, and cell cycle arrest and is a good lead for further development as an EGFR-targeted agent.

4 September 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
MMMohamed F. Mady
Mohamed F. Mady
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
ENEman Nossier
Eman Nossier
AEAhmed F. El-Sayed
Ahmed F. El-Sayed
MHMohamed A. Hawata
Mohamed A. Hawata

25 January 2025 in Applied Water Science
Verified
Journal Article
Open access
PDF file
Safaa R. FoudaSafaa R. Fouda
Safaa R. Fouda
AAAsmaa Abuessawy
Asmaa Abuessawy
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
MEMohamed N. Eisa
Mohamed N. Eisa
MHMohamed A. Hawata
Mohamed A. Hawata
Newly modified magnetic chitosan nanoparticles were synthesized for the high-efficiency removal of cadmium ions from aquatic environments. The structure and morphology of the composites were confirmed using FTIR, TGA, XRD, BET, SEM, TEM, SAED pattern analysis, and zeta potential. Under optimal conditions (pH = 6.0, contact time = 120 min, and sorbent dosage = 0.005 g/100 mL), the maximum removal of Cd (II) by synthesized samples MC, SA, and SB was 90.8%, 95%, and 95.15%, respectively. The kinetic data at optimal pH = 6 could be accurately described using a pseudo-second-order equation, while the Langmuir isotherm model best represented the sorption process. The Langmuir Qmax values for the synthesized nanocomposites S*, S3, S4, S*t, S3t, and S4t were 243.90, 250, 270.27, 212.76, 237.09, and 238.09, respectively. The thermodynamic analysis of these samples shows that the sorption process was exothermic (negative ∆H°) − 15.148, − 13.60, − 13.18, − 18.163, − 16.820, and − 16.06 kJmol−1, respectively. This implies that the diffusion of Cd(II) on the sorbent decreased with the temperature rise. The positive values of ΔS⁰ were 152.37, 147.80, 146.83, 160.94, 157.08, and 154.93 kJmol−1, respectively. The antimicrobial properties of the functionalized sorbents SA and SB were evaluated by measuring the zone of inhibition (ZOI) against Staphylococcus aureus and Klebsiella pneumoniae, representing Gram-negative and Gram-positive bacteria, respectively. SA and SB showed promising activity, demonstrating clear zones of (20 ± 0.2 and 18 ± 0.4 mm), and (22 ± 0.2 and 20 ± 0.4 mm) for S. aureus and K. pneumoniae, respectively. Additionally, these sorbents demonstrated moderate antioxidant activity, with the highest scavenging percentages of 94.20% and 96.63%, respectively, at a concentration of 1000 µg/mL, as assessed by the DPPH method.

Verified
Journal Article
Open access
PDF file
EMEmad Manni
Emad Manni
MFModather Farouk
Modather Farouk
SESarah Adel Elkady
Sarah Adel Elkady
AAAdel A.-H. Abdel-Rahman
Adel A.-H. Abdel-Rahman
MHMohamed A. Hawata
Mohamed A. Hawata
Hagar Sabry El-HemaHagar Sabry El-Hema
Hagar Sabry El-Hema
In response to recent advances in computer-aided drug discovery (CADD) enabled by high-performance computing, computational approaches were employed to support and rationalize the investigation of a VEGFR-2-targeted anticancer candidate, combining molecular-level modeling with experimental validation. Initial in silico ADMET profiling and molecular docking were conducted to support the evaluation of drug-like properties and target engagement within a series of para-toluidine-based derivatives (1–14). The most biologically active compound was further evaluated through 100 ns molecular dynamics simulations and comprehensive DFT calculations to investigate binding stability and electronic characteristics. Based on a rational design strategy and supported by computational analyses, the compounds were synthesized and fully characterized using IR, MS, 1H/13C NMR, and elemental analysis. Biological evaluation was performed against HepG-2, MCF-7, HCT-116, and normal WI-38 cells. Mechanistic studies included VEGFR-2 inhibition, wound-healing migration assays, cell-cycle distribution analysis, apoptosis assessment, and caspase-3 activation. Several derivatives exhibited micromolar cytotoxic activity, with compound 14 emerging as the most active against HepG-2 cells (IC50 = 7.84 ± 0.5 µM), showing cytotoxic activity comparable to that of sorafenib (IC50 = 9.18 ± 0.6 µM) and demonstrating favorable selectivity toward normal WI-38 cells (IC50 = 67.75 ± 3.6 µM). Compound 14 showed moderate VEGFR-2 inhibitory activity (IC50 = 0.55 µM), significant suppression of cell migration, pronounced G0/G1 cell-cycle arrest, and robust apoptosis induction supported by caspase-3 activation. Molecular docking and MD simulations supported a stable binding mode within the VEGFR-2 active site. This integrated framework highlights compound 14 as a selectively active VEGFR-2-oriented anticancer candidate scaffold with a favorable selectivity profile, supported by experimental and computational analyses, warranting further lead optimization.